Is the fossil fuel recovery real, or a stepping stone to a fossil-free future? Register now for our 11/17 webinar at 2PM ET
DUBLIN, October 19, 2021–(BUSINESS WIRE)–The "Global Low Code Development Platform Market Research 2021-2026" report has been added to ResearchAndMarkets.com's offering.
Global Low Code Development Platform Market is likely to grow at a CAGR of around 28% in the forecast period, i.e., 2021-26, primarily due to the rapid digital advancements across several industries and the surging need for digitalization of agile DevOps practices.
Many businesses are rapidly adopting mobile-based apps to make their operations more convenient, efficient, and profitable. The rising need for customization & scalability is another critical aspect further fuelling the market growth. Besides, mobile-based apps expand business abilities and enable owners to explore different possibilities while transforming operational processes to achieve substantial profits. Hence, based on these factors, the overall market is very likely to propel exponentially in the forecast years.
Impact of COVID-19
The outbreak of the Covid-19 pandemic made a positive impact on the Global Market. There has been a gradual increase in the demand for low-code development platforms, and it shall grow in the forecast years. However, with the outbreak, there were increasing challenges where businesses across the world shut. It also brought up challenges in raising the budget post-Covid-19 among the organizations.
Market Segmentation
Cloud Deployment to Witness the Largest Market Share
Based on the Deployment Type, the market bifurcates into On-Premise and Cloud Deployment. Of two, the Cloud Deployment segment is likely to witness the largest share at a significant CAGR in the forecast years.
The cloud-based deployment is cheaper than on-premise storage, offers 24*7 services, and helps obtain data from multiple devices & locations with minimum support and maintenance. It is also beneficial for increasing scalability & management capabilities for developing business applications. Hence, the factors cited above drive the segment growth, thereby fueling the overall market growth in the coming years.
Large Enterprises (LE) to Attain the Fastest Market Growth
Based on the Organization Size, the market classifies into Small & Medium-Sized Enterprises and Large Enterprises. However, the Large Enterprises (LE) segment is more likely to attain the fastest market growth in the forecast years. It owes to the higher budget of Large Enterprises than low or medium-sized enterprises to develop more business apps in less time.
Hence, large enterprises like IT & telecom, BFSI, retail, government, manufacturing, healthcare, and others are gaining full adoption of low code application development platforms in their professions. These factors are likely to lead Large Enterprises to attain the fastest market growth in the forecast years.
Regional Landscape
North America Dominates with the Largest Market Share
North America dominated the global market in recent years and shall continue its dominance in the forecast years by attaining the largest market share. It owes to the availability of various market players dedicatedly delivering low-code development platforms & services to several end-user industries in the North American Market. The US & Canada have strong economic conditions and are likely to be the prominent patrons to the low-code development platform market growth.
Furthermore, partnerships, significant R&D activities, and acquisitions, & mergers are other factors for growth in the deployment of low-code development platforms and services. These enhanced platforms & services are propelling the growth of the market in North America.
Market Driver
The prominent market driver is the rapidly expanding digitalization at the workplace and the trend to Bring-Your-Own-Device, thereby increasing the demand for the low-code development platform market. Besides, the rapid inclination toward a digital workspace with new technologies is another critical aspect that shall create lucrative growth opportunities for the low-code development platform market.
Competitive Landscape
Leading players in the Global Low Code Development Platform Market are
Appian Corporation
Oracle Corporation
Microsoft Corporation
Salesforce
MatsSoft Limited
AgilePoint Inc.
Lansa Inc.
Magic Software Enterprises Ltd.
Kony Inc.
OutSystems Inc.
Pegasystems Inc.
QuickBase Inc.
Zoho
For more information about this report visit https://www.researchandmarkets.com/r/rvxkss
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019006005/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Looking for the next 'big thing'? Cathie Wood knows where to find it.
Buffett is betting big on his favorite company. It might be time to follow suit.
Inflation is at a 31-year high. But these Mad Money megatrends could help you fight back.
Shares of Shopify (NYSE: SHOP) surged 12% to a record closing high of $1,669.52 on Thursday as investors' enthusiasm for the e-commerce leader reached a fevered pitch. Shopify's third-quarter revenue rocketed 46% year over year to $1.1 billion. "Our results show that Shopify is executing well, giving our merchants the tools they need to compete in differentiated ways in a growing number of markets," Chief Financial Officer Amy Shapero said in the company's earnings release.
Yesterday, Sundial issued a press release announcing their financial results for Q3 ended on September 30, 2021. Presenting on this morning's call, we have Zach George, chief executive officer; Jim Keough, chief financial officer; and Andrew Stordeur, president and chief operating officer. Additionally, all financial figures mentioned are in Canadian dollars unless otherwise indicated.
Share prices of AT&T (NYSE: T) hit a 52-week low of $24.54 on Nov. 4 after the company delayed the rollout of its C-band spectrum, a component of its new 5G network, pending an aviation safety review. CEO John Stankey, who took over the top spot last year, is returning AT&T to its telco roots after his predecessor ventured into a number of expensive, entertainment-related acquisitions. A key reason to consider AT&T stock is its wireless business, which has experienced strong growth.
With several electric-vehicle (EV) stocks charging up this week, QuantumScape (NYSE: QS) couldn't be left far behind. Shares of the EV battery technology company had shot up 23.6% this week as of 1:30 p.m. EST Friday, according to data from S&P Global Market Intelligence. The passage of a long-awaited infrastructure bill and growth moves from QuantumScape this week powered the stock higher.
After the recent pullback, the big data specialist's stock is now down roughly 3.5% year to date.
Our call of the day from JonesTrading's chief strategist Michael O'Rourke says investors are ignoring history and a stock-market bubble that's bound to burst.
In this article, we reviewed Philip Best’s investment philosophy and portfolio management strategies. We also examined the top 10 stock picks of Philip Best’s Quaero Capital. You can skip our comprehensive list and detailed analysis and jump directly to the Top 5 Stock Picks of Philip Best’s Quaero Capital. Philip Best is the portfolio manager, […]
Inflation, labor shortages, and a besieged Fed are dominating headlines. So why isn't the market listening?
The breakup of General Electric puts the final nail in the coffin of the corporate conglomerate business model, writes Jeffrey Sonnenfeld.
Tesla CEO Elon Musk has been selling shares of the electric carmaker — and he may soon sell a lot more.
These companies are recommended by at least three top-performing newsletters and have low valuations.
Pharmaceutical giant Merck (NYSE: MRK) has recently made headlines with its oral COVID-19 pill that was just approved in the U.K. Its competitor, Bristol Myers Squibb (NYSE: BMY), is looking to start reaping rewards from a late 2020 purchase of heart medication specialist MyoKardia. George Budwell (Bristol Myers Squibb): With its shares trading at less than three times sales over the prior 12-month period, Bristol Myers Squibb is easily one of the cheapest big pharma stocks right now. First off, Bristol didn't take part in the COVID vaccine bonanza, which has been a key growth driver for several of its peers this year.
In this article, we discuss the 10 best stocks to make money. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Stocks to Make Money. Investing in equities is a trusted and reliable method for building long-term wealth. However, even though it is relatively easier to identify […]
Investors have priced in their perception of the present inflation situation. Veteran investors know, however, that perceptions can sometimes be wrong, setting up great buying opportunities as a result. Take Campbell Soup as an example.
In this article, we discuss the top 10 stocks in Glen Kacher’s Light Street Capital’s portfolio. If you want to skip our detailed analysis of Kacher’s history, investment philosophy, and hedge fund performance, go directly to Light Street Capital Portfolio: Top 5 Stocks. Light Street Capital is a Palo Alto-based investment management firm, that primarily invests […]
Investors are constantly looking for stocks that will yield massive returns. That being said, finding these stocks can seem like an overwhelming task. Not to mention it can be expensive. Some of the most well-known names like Amazon and Alphabet can put you out thousands of dollars for just a single share. However, snapping up stocks with strong long-term growth prospects doesn’t have to cost you your entire savings. Using the TipRanks database, we were able to pinpoint two stocks with massive u
Remember Inovio (INO), the small biotech punching above its weight and mingling with pharma giants in the early attempts to stamp out the Covid-19 pandemic? The company was one of the frontrunners in the race to bring a Covid vaccine to market, but that was eons ago in stock market terms with the stock only trending in one direction (down) since mid-2020’s improbable peaks. Inovio has struggled to get its Covid-19 DNA vaccine INO-4800 beyond the mid-stage of testing (at least in the US), and in

source

Leave a Reply